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Transforming growth factors (TGFs) induce anchorage-
independent growth in soft agar of certain untransformed
fibroblast target cells (Rizzino et al., 1986). This reversible
'transformed phenotype' is brought about by the synergistic
interaction of two TGFs, TGFa and TGFP, in the presence
of PDGF and other growth factors, including serum factors
(Rizzino et al., 1986).
TGFa is a 5.6 kDa single chain polypeptide, closely related
to epidermal growth factor (EGF) (Marquardt et al., 1983),
which binds to the EGF membrane receptor (Todaro et al.,
1980). TGFa has mitogenic effects very similar to those of
EGF (Barrandon and Green, 1987). TGFa is produced by
human keratinocytes (Coffey et al., 1987), some types of
human tumour cells (Coffey et al., 1986; Todaro et al., 1980)
and some virally transformed cells (Marquardt et al., 1983).
TGF,B in the active form is a 25 kDa homodimer which
binds to a specific cell membrane receptor on fibroblast and
epithelial cells (Wakefield et al., 1987). The biological effects
of TGF,B depend on the indicator system used. TGFP
stimulates the proliferation of most mesenchymally derived
cell types, but is inhibitory for normal epithelial cells (Shipley
et al., 1986), and several kinds of human tumour cells
(Roberts et al., 1985). Under certain culture conditions the
inhibitory effects of TGFB on human keratinocytes are
irreversible, resulting in the induction of terminal
differentiation (Reiss & Sartorelli, 1987). TGF,B is commonly
released in vitro by both fibroblast and epithelial cells as a
high molecular weight latent form (Lyons et al., 1988;
Miyazono et al., 1988), which is inactive, probably due to its
inability to bind to its receptor (Wakefield et al., 1987).
Latent TGFP can be irreversibly activated following acid
treatment (Lyons et al., 1988). However, the actual
physiological mechanism of activation is unknown, although
proteolytic activation by plasmin, a wide spectrum serine
protease, has been demonstrated in vitro (Lyons et al., 1988).
The production of TGFs by normal cells in vitro (Coffey et
al., 1987; Shipley et al., 1986) has stimulated interest in their
roles in cell growth regulation. There is some evidence for the
autocrine growth regulation by TGFs of keratinocyte pro-
liferation (Coffey et al., 1987; Shipley et al., 1986). TGFa
stimulates the proliferation of the keratinocytes that secrete it
(Coffey et al., 1987). Keratinocytes apparently release TGFI
as well, but in the latent form (Shipley et al., 1986). Bron-
chial epithelial cells can probably activate the latent form
(Masui et al., 1986), and this may also be true for
keratinocytes. Hence for normal keratinocytes autocrine
stimulation by TGFa and autocrine inhibition by TGFP may
be normal processes, and changes in either of these autocrine
pathways may be important in neoplastic transformation of
stratified squamous epithelia (Moses et al., 1987).
Recently, Lee et al. (1987) have described a reciprocal
effect of EGF and TGFP on anchorage-dependent and
anchorage-independent growth of A431 epidermoid car-
cinoma cells. They found that EGF inhibited surface culture
growth but stimulated soft agar growth; platelet-derived h-
TGFP gave opposite results. By adding these factors
together, it was found that the stimulatory effects of TGFP
on monolayer culture were antagonised by EGF and those of
EGF on soft-agar growth were antagonised by TGFI3.
Our purpose was (a) to see whether this was a more
general phenomenon and (b) to establish whether the cell line
we used was capable of secreting significant amounts of
TGFa and TGFP, data which could help us to understand
why certain SCCs grow in soft agar and most others do not
(Rheinwald & Beckett, 1981).
SNO is an established human oesophageal carcinoma cell
line (Bey et al., 1976), subcultured in DMEM + 5% fetal calf
serum (FCS), and which is highly tumorigenic; one or two
million cells injected suprascapularly in a nude mouse pro-
duce a tumour usually in less than a month without excep-
tion (data not shown). When the cultures of SNO cells grown
in 10 or 14 cm culture dishes were 80% confluent, they were
washed three times at 2-h intervals with serum-free DMEM,
then washed once for 18 h with serum-free DMEM, and then
24-h conditioned medium (CM) was collected. The protein
content of serum-free CM after 24 h was approximately
3-5 tig ml-' as determined by a dye-binding assay (Lowry et
al., 1951). CM was concentrated five times (Amicon YM5
ultrafiltration membrane) before being used in the '251I-EGF
competition assay as described in Carpenter (1985). The 125I1
TGFJ3 competition assays were performed as described in
Wakefield et al. (1987) using unconcentrated acidified CM.
The data are presented as the mean of triplicate assays.
For the soft agar assays, CM was fractionated and concent-
rated 10-fold on XM50 and PM 10 Amicon ultrafiltration
membranes, before acidification by addition of 1 N HCI to
pH 1.5, followed by neutralisation at 4'C to produce acid-
ified CM (ACM). For the soft agar assays, a base layer of
0.5% agar in DMEM was added to 24-well culture plates.
Once the base layer had solidified, a second layer of agar
(0.3% in DMEM) containing the cells, (5 x 103 per well for
NRK-49F, obtained from the American Type Culture Col-
lection, 104 per well for SNO), serum (10% FCS) and growth
factors (EGF, Sigma; human platelet-derived TGF01 (h-
TGFPI), R & D Systems, Minneapolis, MN, USA) or ACM
fractions (0.25 ml per well), with or without specific neutra-
lising anti-TGFP antibodies (R and D systems, Mineapolis,
MN, USA). After 7 days the number of colonies that formed
was assessed using a micrometer eyepiece. Colonies >50 tim
in diameter were scored as positive and the data are exp-
ressed as the mean ± standard deviation.
The colony forming efficiency (CFE) of SNO cells to which
EGF, h-TGFPI or EGF and h-TGFPI had been added was
assessed by growing 103 cells seeded into 6 cm dishes for
10- 14 days and then staining and counting the colonies
under a dissecting microscope.
The ability of some human tumour cells to form progres-
sively growing colonies in soft agar has been correlated with
autocrine growth factor production (Halper & Moses, 1987),
including TGFa secretion (Todaro et al., 1980). In contrast,
Kudlow et al. (1984) found no evidence for autocrine growth
stimulation in a TGFa-secreting melanoma cell line that
expressed EGF receptors.
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Our EGF competition assays showed that SNO cells in
monolayer culture do not secrete a factor which competes for
the EGF receptors (Table I). In conformity with other
oesophageal SCC cell lines (Ozawa et al., 1987), SNO cells
express higher than normal numbers of EGF/TGFx receptors
(2.6 x 106 receptors per cell, Kd = 1.4 nM; Veale & Thornley,
1989) and their proliferation in monolayer culture is inhibited
by EGF (Figure 1) (Kamata et al., 1986). In these respects,
and also because SNO cells are stimulated by EGF in soft
agar culture (Figure 2a,b), SNO cells are similar to A431
cells as described by Lee et al. (1987). Because we did not
detect competition at the EGF binding site on SNO cells by
concentrated CM, our findings seem to rule out an external
autocrine stimulatory pathway involving TGFa. However,
SNO cells may synthesise TGFx mRNA but secrete no or
very little TGFx into the culture medium, as occurs in A431
cells and other human tumour cell lines (Derynck et al.,
1986, 1987).
Our results suggest that SNO cells secrete low levels of a
TGFI-like factor. Table II shows that concentrated ACM
stimulates the soft agar growth of NRK-49F cells and that
this activity is specifically neutralised by antibodies to TGFP
(Table III). In vitro, TGFP is a 'bifunctional' regulator of
cellular growth, acting as both a growth stimulator and a
growth inhibitor, depending on the cell type and the culture
conditions. It is inhibitory for normal epithelial cells and
some SCC cell lines, which display a variable response in
monolayer culture. SNO cells, unlike A431 cells, retain this
inhibitory pathway (Figure 1). Furthermore, addition of
EGF and TGFPI had an additive effect producing almost no
growth at all (Figure 1). Our results from the competition
assays and antibody neutralising studies suggest that SNO
cells secrete only about 70-100pg per 106 cells per 24 h of
this TGFI3-like factor, an amount which is comparable to the
amounts secreted by several different types of human
tumours (Wakefield et al., 1987).
Table I Competition assays with SNO conditioned medium
2sI-EGF bound '25I-TGFP bound to
% SNO CM or to SNO cells NRK-49F cells
ACM added (% ofcontrol) (% ofcontrol)
25 108 100
50 95 97
75 103 94
100 102 82
In the '251-EGF competition assay, I ng '251-EGF was used to
compete with 0-100% CM for binding to SNO EGF receptors. In the
'25I-TGFP competition assay, 0.25 ng '251-TGFP was used to compete
with 0- 100% ACM for binding to NRK-49F TGFP receptors.
Table II Effects of fractionated SNO ACM on NRK-49F and SNO
colony formation in soft agar
NRK-49F colonies SNO colonies
per well per well
Control 600± 180 1030±70
>XM50 ACM 2380±440 800± 120
<XM50, >PMIO ACM 640±200 860± 180
The control and test wells contained 4 ng ml-' EGF.
Table III Effect of anti-TGF P1 neutralising antibodies (IgG) on the
TGF P-like activity in SNO ACM
NRK-49F colonies
per well
Control 120±20
>XM50 ACM 1040±240
>XM50 ACM treated with anti-TGF P 280±80
antibodies
The addition of 10jug of antibodies to the SNO ACM fraction
(125p1) reduced the level of TGF activity to that present in serum.
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Figure 1 Effects of EGF and h-TGFPl on the colony-forming
efficiency of SNO cells in surface culture. I03 SNO cells per 6 cm
culture dish were plated out in triplicate. After allowing 24h for
cell attachment to the culture dish, the medium was replaced with
medium containing the growth factors at the indicated concentra-
tions. The cultures were grown for 10-14 days (refed after 7
days) before fixing and staining.
It is well established that TGFP is secreted in a latent
form, probably as a high molecular weight complex
associated with a carrier protein(s), one of which may be a
protease (Miyazono et al., 1988). The subsequent processing
of this complex to the 25 kDa active form is only now
becoming clear (Lyons et al., 1988). The soft agar growth of
SNO cells is inhibited to a small degree by concentrated
ACM (Table II) and platelet-derived TGFP1 at concentra-
tions of up to 10 ng ml-' (Figure 2a). Quite clearly, however,
exogenous TGFII can antagonise, and to a large extent
eliminate, the stimulatory effect of EGF under these condi-
tions (Figure 2b), as it does in A431 cells (Lee et al., 1987).
SNO cells therefore share only some of the properties of
A431 growth regulation in vitro; the reciprocal effects of
EGF and TGFP that Lee et al. (1987) observed may not be a
general feature of those SCCs capable of anchorage-
independent growth.
At this stage it cannot be said that those SCCs which grow
well in soft agar supplemented with serum, and are often
tumorigenic, are those with an extracellular 'autocrine' path-
way involving TGFa, since we found no significant TGFx
secretion by SNO cells, although high numbers of the EGF/
TGFa receptor are expressed by this cell line. On the other
hand, those cell lines-that secrete TGFI, in monolayer culture
may grow vigorously in soft agar, even in the presence of
high concentrations of TGF3.
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Figure 2 a, Effects of EGF and h-TGFPI on the colony-forming
efficiency of SNO cells in soft agar. b, The antagonistic effect of
h-TGFPI on the EGF-induced stimulation of SNO colony for-
mation in soft agar. EGF and h-TGFPI were added at the
concentrations indicated to 104 cells per well, and the number of
colonies >501tm in diameter was quantified after I week of
incubation.
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